News headlines about Neurocrine Biosciences (NASDAQ:NBIX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.55952047056 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s rankings:
- Neurocrine Biosciences, Inc. (NBIX) Expected to Post Q4 2018 Earnings of $0.43 Per Share (americanbankingnews.com)
- Neurocrine Biosciences, Inc. (NBIX) Stock Technical Analysis – Wall Street Morning (wallstreetmorning.com)
- Are Analysts Optimistic About: Rayonier Advanced Materials Inc. (RYAM) and Neurocrine Biosciences, Inc. (NBIX) – NMSU Nеws (nmsunews.com)
- Neurocrine Biosciences, Inc. (NBIX) Stock Showing Pleasant/Unpleasant Sentiment – Investing News Update (investingbizz.com)
- FY2019 EPS Estimates for Neurocrine Biosciences, Inc. Lowered by Analyst (NBIX) (americanbankingnews.com)
A number of analysts have commented on NBIX shares. Jefferies Group boosted their target price on Neurocrine Biosciences to $105.00 and gave the stock a “buy” rating in a research report on Friday, January 5th. Oppenheimer set a $85.00 target price on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Leerink Swann boosted their target price on Neurocrine Biosciences from $90.00 to $96.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 20th. JPMorgan Chase & Co. boosted their target price on Neurocrine Biosciences from $79.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. Finally, Barclays reiterated an “overweight” rating and set a $100.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, February 14th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $95.23.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.11). The firm had revenue of $94.52 million during the quarter, compared to analyst estimates of $94.00 million. During the same quarter in the prior year, the company earned ($0.51) EPS. sell-side analysts forecast that Neurocrine Biosciences will post -0.23 EPS for the current year.
In other news, insider Haig P. Bozigian sold 1,625 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $79.12, for a total value of $128,570.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Darin Lippoldt sold 15,237 shares of the company’s stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $75.00, for a total value of $1,142,775.00. Following the completion of the sale, the insider now owns 28,394 shares in the company, valued at $2,129,550. The disclosure for this sale can be found here. Insiders sold 399,589 shares of company stock worth $32,443,795 over the last 90 days. Company insiders own 4.80% of the company’s stock.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.